|
1
|
National Cancer Institute, . Cancer
statistics: SEER stat fact sheets, breast cancer. http://seer.cancer.gov/statfacts/html/breast.html
|
|
2
|
Bouchalova P, Nenutil R, Muller P, et al:
Mutant p53 accumulation in human breast cancer is not an intrinsic
property or dependent on structural or functional disruption but is
regulated by exogenous stress and receptor status. J Pathol.
233:238–246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harris L, Fritsche H, Mennel R, et al:
American Society of Clinical Oncology 2007 update of
recommendations for the use of tumor markers in breast cancer. J
Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin Q, Liu Y, Chen H, et al: Survivin,
Ki-67 and tumor grade as predictors of response to docetaxel-based
neoadjuvant chemotherapy in locally advanced breast cancer. Mol
Clin Oncol. 1:839–844. 2013.PubMed/NCBI
|
|
5
|
Mason BH, Holdaway IM, Mullins PR, Yee LH
and Kay RG: Progesterone and estrogen receptors as prognostic
variables in breast cancer. Cancer Res. 43:2985–2990.
1983.PubMed/NCBI
|
|
6
|
Ogston KN, Miller ID, Payne S, et al: A
new histological grading system to assess response of breast
cancers to primary chemotherapy: Prognostic significance and
survival. Breast. 12:320–327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peppercorn J, Perou CM and Carey LA:
Molecular subtypes in breast cancer evaluation and management:
Divide and conquer. Cancer Invest. 26:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feeley LP, Mulligan AM, Pinnaduwage D,
Bull SB and Andrulis IL: Distinguishing luminal breast cancer
subtypes by Ki67, progesterone receptor or TP53 status provides
prognostic information. Mod Pathol. 27:554–561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chambers AF, Naumov GN, Varghese HJ, et
al: Critical steps in hematogenous metastasis: An overview. Surg
Oncol Clin N Am. 10:243–255. 2001.PubMed/NCBI
|
|
10
|
Saaristo A, Karpanen T and Alitalo K:
Mechanisms of angiogenesis and their use in the inhibition of tumor
growth and metastasis. Oncogene. 19:6122–6129. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Woodhouse EC, Chuaqui RF and Liotta LA:
General mechanisms of metastasis. Cancer. 80(Suppl): S1529–S1537.
1997.
|
|
12
|
Min KW, Kim DH, Do SI, et al: Diagnostic
and prognostic relevance of MMP-11 expression in the stromal
fibroblast-like cells adjacent to invasive ductal carcinoma of the
breast. Ann Surg Oncol. 20(Suppl 3): S433–S442. 2013.PubMed/NCBI
|
|
13
|
Jiang P, Enomoto A and Takahashi M: Cell
biology of the movement of breast cancer cells: Intracellular
signalling and the actin cytoskeleton. Cancer Lett. 284:122–130.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Edwards RA and Bryan J: Fascins, a family
of actin bundling proteins. Cell Motil Cytoskeleton. 32:1–9. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mosialos G, Yamashiro S, Baughman RW, et
al: Epstein-Barr virus infection induces expression in B
lymphocytes of a novel gene encoding an evolutionarily conserved
55-kilodalton actin-bundling protein. J Virol. 68:7320–7328.
1994.PubMed/NCBI
|
|
16
|
Hashimoto Y, Skacel M and Adams JC: Roles
of fascin in human carcinoma motility and signaling: Prospects for
a novel biomarker? Int J Biochem Cell Biol. 37:1787–1804. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hsu KF, Lin CK, Yu CP, et al: Cortactin,
fascin, and survivin expression associated with clinicopathological
parameters in esophageal squamous cell carcinoma. Dis Esophagus.
22:402–408. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Al-Alwan M, Olabi S, Ghebeh H, et al:
Fascin is a key regulator of breast cancer invasion that acts via
the modification of metastasis-associated molecules. PLoS One.
6:e273392011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hashimoto Y, Skacel M, Lavery IC, et al:
Prognostic significance of fascin expression in advanced colorectal
cancer: An immunohistochemical study of colorectal adenomas and
adenocarcinomas. BMC Cancer. 6:2412006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pelosi G, Pastorino U, Pasini F, et al:
Independent prognostic value of fascin immunoreactivity in stage I
nonsmall cell lung cancer. Br J Cancer. 88:537–547. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hashimoto Y, Shimada Y, Kawamura J, et al:
The prognostic relevance of fascin expression in human gastric
carcinoma. Oncology. 67:262–270. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tong GX, Yee H, Chiriboga L, Hernandez O
and Waisman J: Fascin-1 expression in papillary and invasive
urothelial carcinomas of the urinary bladder. Hum Pathol.
36:741–746. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tan VY, Lewis SJ, Adams JC and Martin RM:
Association of fascin-1 with mortality, disease progression and
metastasis in carcinomas: A systematic review and meta-analysis.
BMC Med. 11:522013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grothey A, Hashizume R, Sahin AA and
McCrea PD: Fascin, an actin-bundling protein associated with cell
motility, is upregulated in hormone receptor negative breast
cancer. Br J Cancer. 83:870–873. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoder BJ, Tso E, Skacel M, et al: The
expression of fascin, an actin-bundling motility protein,
correlates with hormone receptor-negative breast cancer and a more
aggressive clinical course. Clin Cancer Res. 11:186–192.
2005.PubMed/NCBI
|
|
26
|
Esnakula AK, Ricks-Santi L, Kwagyan J, et
al: Strong association of fascin expression with triple negative
breast cancer and basal-like phenotype in African-American women. J
Clin Pathol. 67:153–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Robbins P, Pinder S, de Klerk N, et al:
Histological grading of breast carcinomas: A study of interobserver
agreement. Hum Pathol. 26:873–879. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Edge SB, Byrd DR, Compton CC, et al: AJCC
Cancer Staging Manual. 7th. Springer; New York, NY, USA: 2010
|
|
29
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
30
|
Carey LA, Perou CM, Livasy CA, et al:
Race, breast cancer subtypes, and survival in the Carolina Breast
Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wolff AC, Hammond ME, Hicks DG, et al:
American Society of Clinical Oncology; College of American
Pathologists: Recommendations for human epidermal growth factor
receptor 2 testing in breast cancer: American Society of Clinical
Oncology/College of American Pathologists clinical practice
guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.PubMed/NCBI
|
|
33
|
Jayo A and Parsons M: Fascin: A key
regulator of cytoskeletal dynamics. Int J Biochem Cell Biol.
42:1614–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li A, Dawson JC, Forero-Vargas M, et al:
The actin-bundling protein fascin stabilizes actin in invadopodia
and potentiates protrusive invasion. Curr Biol. 20:339–345. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Matsudaira P: Actin crosslinking proteins
at the leading edge. Semin Cell Biol. 5:165–174. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vignjevic D, Schoumacher M, Gavert N, et
al: Fascin, a novel target of beta-catenin-TCF signaling, is
expressed at the invasive front of human colon cancer. Cancer Res.
67:6844–6853. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oh SY, Kim YB, Suh KW, et al: Prognostic
impact of fascin-1 expression is more significant in advanced
colorectal cancer. J Surg Res. 172:102–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Puppa G, Maisonneuve P, Sonzogni A, et al:
Independent prognostic value of fascin immunoreactivity in stage
III-IV colonic adenocarcinoma. Br J Cancer. 96:1118–1126. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roh MS, Um SJ, Choi Y, et al: Prognostic
significance of fascin expression in stage I non-small cell lung
cancer. Tuberc Respir Dis (Seoul). 65:105–109. 2008. View Article : Google Scholar
|
|
40
|
Xing P, Li JG, Jin F, et al: Fascin, an
actin-bundling protein, promotes breast cancer progression in
vitro. Cell Biochem Funct. 29:303–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie JJ, Xu LY, Wu JY, et al: Involvement
of CYR61 and CTGF in the fascin-mediated proliferation and
invasiveness of esophageal squamous cell carcinomas cells. Am J
Pathol. 176:939–951. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gu MJ, Kim JY and Park JB: Fascin
expression predicts lymph node metastasis and worse survival in
small intestinal carcinoma. Pathology. 46:21–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
